About 1130.1130 Group offers research & development of ancillary inhalation devices with focus on 420 & 710 formulations. Having a long-history with US medical devices, and engineering, the design began in NY which led to the US Patented "flagship" technology. 1130 developed a new starting point for end-users to consume extracts. In turn, this secures a strong platform to expand our inhalation methods while current industry standards are destined to ALL fail future FDA compliance and regulation.
|
Established in 2021After conception in 2016, the Clarity Pen® system began initial prototyping and engagement with industry leaders. Quickly identifying multiple-deficits surrounding inhalation devices it was clear to our pioneers that this "better process / technique" would sustain future regulation & compliance the maturing industry was missing. This clear vision of the deficits surrounding the efficacy of inhalation medicaments, lead to an investment in a CE, RoHS electronics company in Shenzhen, China, and begun to fight for the US patent protection which was later received Aug 2021.
|
Our GoalIt was clear to us from the start that "air activated" cartridges which contained filaments inside the pre-filled hardware expedited the degradation of the extracts well before the end-user had a chance to benefit from it. This obvious shortfall, leads us to the second deficit; transportation. How do environmental conditions play into the efficacy of the pre-filled extracts? Oxidation & outside contaminants are seen immediately after leaving the lab and begin its journey through ground and air transportation, left to sit on the shelf to later be acquired.
|
Our Advisors.
we're Here for You Contact Us.With manufacturing partners an supply chains throughout the world, we are able to accept your inquiry and respond within 24hrs.
|